• Home
  • Publications
  • Evaluation of fibrinogen concentration by clot firmness using a dielectric blood coagulation test system

Research Area

Author

  • Yulin Zeng*, Yudai Yamamoto*, Yoshihito Hayashi, Tokujiro Uchida*

Company

  • Sony Group Corporation

Venue

  • Journal of Anesthesia

Date

  • 2022

Share

Evaluation of fibrinogen concentration by clot firmness using a dielectric blood coagulation test system

View Publication

Abstract

Purpose
To determine if fibrinogen concentration can be evaluated by dielectric permittivity changes in dielectric blood coagulation testing (DBCM) during cardiovascular surgery with cardiopulmonary bypass (CPB).

Methods
We performed a single-center prospective observational study at a university hospital. One hundred patients undergoing cardiovascular surgery with CPB were enrolled. Whole-blood samples were obtained after weaning from CPB, and dielectric clot strength (DCS) was measured by intrinsic pathway testing with or without heparinase in DBCM. The FIBTEM test was performed during rotational thromboelastometry using the same samples, and maximum clot firmness (MCF) was evaluated. Spearman’s correlation analysis was performed, and receiver operating characteristics (ROC) curve analyses were used to evaluate the performance of hypofibrinogenemia detection.

Results
DCS showed a strong positive correlation with plasma fibrinogen concentration (Rs = 0.76, P < 0.0001). The area under the ROC curve for evaluating plasma fibrinogen concentration < 200 mg/dL was 0.91 (95% confidence interval (CI) 0.85–0.97) for DCS, compared with 0.88 (95% CI 0.81–0.94) for FIBTEM MCF. The optimal cutoff value of DCS was 17.0 (sensitivity 94%, specificity 80%).

Conclusions
DCS variables showed a significantly strong correlation with plasma fibrinogen concentration, and the diagnostic performance for hypofibrinogenemia was comparable to that for FIBTEM MCF. This novel methodology has the potential to provide a point-of-care test with sufficient accuracy for the detection of perioperative hypofibrinogenemia during cardiovascular surgery with CPB.

Share

この記事をシェアする